KBC Group
VIR icon

KBC Group’s Vir Biotechnology VIR Stock Holding History

KBC Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$92K Buy
+8,193
New +$81.9K ﹤0.01% 1439
2025
Q2 		– Sell
-5,958
Closed -$39K – 1816
2025
Q1 		$39K Sell
5,958
-3,012
-34% -$26.8K ﹤0.01% 1833
2024
Q4 		$66K Buy
8,970
+5,177
+136% +$40.8K ﹤0.01% 1759
2024
Q3 		$28K Hold
3,793
– – ﹤0.01% 1832
2024
Q2 		$34K Buy
3,793
+1,274
+51% +$12.2K ﹤0.01% 1794
2024
Q1 		$26K Hold
2,519
– – ﹤0.01% 1801
2023
Q4 		$25K Hold
2,519
– – ﹤0.01% 1845
2023
Q3 		$24K Sell
2,519
-2,980
-54% -$42.5K ﹤0.01% 1857
2023
Q2 		$135K Sell
5,499
-587
-10% -$14.7K ﹤0.01% 1076
2023
Q1 		$142K Sell
6,086
-617
-9% -$15.8K ﹤0.01% 1084
2022
Q4 		$170K Hold
6,703
– – ﹤0.01% 1022
2022
Q3 		$129K Hold
6,703
– – ﹤0.01% 1093
2022
Q2 		$171K Buy
+6,703
New +$156K ﹤0.01% 1032

Other funds holding VIR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

KBC Group's VIR Position: Q3 2026 in Review

KBC Group opened a new position in Vir Biotechnology (VIR) in Q3 2026: 8,193 shares worth $92K. The stake represents ﹤0.01% of the portfolio and ranks #1439 among its holdings. This is a return to the name: KBC Group previously reported a position in VIR as recently as Q1 2025.

KBC Group first reported a position in VIR in Q2 2022 and has held it in 13 quarters since. The position peaked at $171K in Q2 2022. 202 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • KBC Group held 8,193 shares of Vir Biotechnology worth $92K as of Q3 2026.
  • Vir Biotechnology was a new KBC Group position in Q3 2026.
  • Vir Biotechnology made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1439 holding.
  • KBC Group first reported a position in Vir Biotechnology in Q2 2022 and has held it in 13 quarters since.
  • KBC Group's Vir Biotechnology position peaked at $171K in Q2 2022.
  • 202 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.